IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China
The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world. We collected blood samples from 132 PLWH aged 18–59 years who were vaccinated with two doses of BBIBP-CorV vaccine (Sinopharm) or CoronaVac...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/6/880 |
| _version_ | 1797481617513512960 |
|---|---|
| author | Guang Zeng Liumei Xu Shuidong Feng Jie Tang Xiaohui Wang Guilian Li Yongxia Gan Chenli Zheng Jin Zhao Zhengrong Yang |
| author_facet | Guang Zeng Liumei Xu Shuidong Feng Jie Tang Xiaohui Wang Guilian Li Yongxia Gan Chenli Zheng Jin Zhao Zhengrong Yang |
| author_sort | Guang Zeng |
| collection | DOAJ |
| description | The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world. We collected blood samples from 132 PLWH aged 18–59 years who were vaccinated with two doses of BBIBP-CorV vaccine (Sinopharm) or CoronaVac vaccine (SinoVac) at 28 ± 7 days and 180 ± 20 days the after second dose, to detect the level of Spike receptor binding domain-protein specific IgG (S-RBD-IgG) by using chemiluminescence. We found that the BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody seropositivity rates and levels in PLWH than in healthy controls (HCs). The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower humoral immune responses in PLWH, having lower CD4<sup>+</sup>T cell counts (<350 cells/μL) compared to PLWH, and having higher CD4<sup>+</sup>T cell counts (≥350 cells/μL) after a second dose of vaccination. The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody levels in PLWH, having CD4<sup>+</sup>T cell counts ≥350 cells/μL compared to HCs. No negative effects were observed in terms of the CD4<sup>+</sup>T cell counts and HIV RNA viral load (VL) of PLWH after vaccination. Ninety-nine PLWH and eighty-three HCs completed a second blood collection for testing; we found a statistically significant decrease in the humoral immune response both in PLWH and HCs from 28 days to 180 days after a second dose of BBIBP-CorV vaccine or CoronaVac vaccine. The S-RBD-IgG antibody induced by the BBIBP-CorV vaccine or the CoronaVac vaccine declined faster in the PLWH population than in the healthy population, and two doses of the BBIBP-CorV vaccine or the CoronaVac vaccine may not be enough to provide PLWH with persistent immunity against SARS-CoV-2. It is necessary for PLWH to be prioritized for a third dose over the healthy population, but the immunogenicity of the third dose of the homologous or heterologous vaccine requires further study. |
| first_indexed | 2024-03-09T22:17:09Z |
| format | Article |
| id | doaj.art-454a91b6987d4b9f868542f67a400c5c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:17:09Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-454a91b6987d4b9f868542f67a400c5c2023-11-23T19:20:47ZengMDPI AGVaccines2076-393X2022-05-0110688010.3390/vaccines10060880IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, ChinaGuang Zeng0Liumei Xu1Shuidong Feng2Jie Tang3Xiaohui Wang4Guilian Li5Yongxia Gan6Chenli Zheng7Jin Zhao8Zhengrong Yang9School of Public Health, University of South China, Hengyang 421001, ChinaThe Third People’s Hospital of Shenzhen, Shenzhen 518020, ChinaSchool of Public Health, University of South China, Hengyang 421001, ChinaSchool of Public Health, University of South China, Hengyang 421001, ChinaDepartment of HIV/STDS Prevention and Control, Shenzhen Center for Disease Prevention and Control, Shenzhen 518055, ChinaDepartment of HIV/STDS Prevention and Control, Shenzhen Center for Disease Prevention and Control, Shenzhen 518055, ChinaDepartment of HIV/STDS Prevention and Control, Shenzhen Center for Disease Prevention and Control, Shenzhen 518055, ChinaDepartment of HIV/STDS Prevention and Control, Shenzhen Center for Disease Prevention and Control, Shenzhen 518055, ChinaDepartment of HIV/STDS Prevention and Control, Shenzhen Center for Disease Prevention and Control, Shenzhen 518055, ChinaSchool of Public Health, University of South China, Hengyang 421001, ChinaThe purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world. We collected blood samples from 132 PLWH aged 18–59 years who were vaccinated with two doses of BBIBP-CorV vaccine (Sinopharm) or CoronaVac vaccine (SinoVac) at 28 ± 7 days and 180 ± 20 days the after second dose, to detect the level of Spike receptor binding domain-protein specific IgG (S-RBD-IgG) by using chemiluminescence. We found that the BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody seropositivity rates and levels in PLWH than in healthy controls (HCs). The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower humoral immune responses in PLWH, having lower CD4<sup>+</sup>T cell counts (<350 cells/μL) compared to PLWH, and having higher CD4<sup>+</sup>T cell counts (≥350 cells/μL) after a second dose of vaccination. The BBIBP-CorV vaccine or the CoronaVac vaccine induced lower S-RBD-IgG antibody levels in PLWH, having CD4<sup>+</sup>T cell counts ≥350 cells/μL compared to HCs. No negative effects were observed in terms of the CD4<sup>+</sup>T cell counts and HIV RNA viral load (VL) of PLWH after vaccination. Ninety-nine PLWH and eighty-three HCs completed a second blood collection for testing; we found a statistically significant decrease in the humoral immune response both in PLWH and HCs from 28 days to 180 days after a second dose of BBIBP-CorV vaccine or CoronaVac vaccine. The S-RBD-IgG antibody induced by the BBIBP-CorV vaccine or the CoronaVac vaccine declined faster in the PLWH population than in the healthy population, and two doses of the BBIBP-CorV vaccine or the CoronaVac vaccine may not be enough to provide PLWH with persistent immunity against SARS-CoV-2. It is necessary for PLWH to be prioritized for a third dose over the healthy population, but the immunogenicity of the third dose of the homologous or heterologous vaccine requires further study.https://www.mdpi.com/2076-393X/10/6/880PLWHBBIBP-CorV vaccineCoronaVac vaccineS-RBD-IgGCD4<sup>+</sup>T cellviral load |
| spellingShingle | Guang Zeng Liumei Xu Shuidong Feng Jie Tang Xiaohui Wang Guilian Li Yongxia Gan Chenli Zheng Jin Zhao Zhengrong Yang IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China Vaccines PLWH BBIBP-CorV vaccine CoronaVac vaccine S-RBD-IgG CD4<sup>+</sup>T cell viral load |
| title | IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China |
| title_full | IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China |
| title_fullStr | IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China |
| title_full_unstemmed | IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China |
| title_short | IgG Antibody Responses and Immune Persistence of Two Doses of BBIBP-CorV Vaccine or CoronaVac Vaccine in People Living with HIV (PLWH) in Shenzhen, China |
| title_sort | igg antibody responses and immune persistence of two doses of bbibp corv vaccine or coronavac vaccine in people living with hiv plwh in shenzhen china |
| topic | PLWH BBIBP-CorV vaccine CoronaVac vaccine S-RBD-IgG CD4<sup>+</sup>T cell viral load |
| url | https://www.mdpi.com/2076-393X/10/6/880 |
| work_keys_str_mv | AT guangzeng iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT liumeixu iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT shuidongfeng iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT jietang iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT xiaohuiwang iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT guilianli iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT yongxiagan iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT chenlizheng iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT jinzhao iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina AT zhengrongyang iggantibodyresponsesandimmunepersistenceoftwodosesofbbibpcorvvaccineorcoronavacvaccineinpeoplelivingwithhivplwhinshenzhenchina |